MEDI5752
MEDI5752 is a pharmaceutical drug with 6 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
4
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
MEDI5752 in Japanese Patients With Advanced Solid Tumors.
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
Clinical Trials (6)
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
MEDI5752 in Japanese Patients With Advanced Solid Tumors.
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6